<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01150526</url>
  </required_header>
  <id_info>
    <org_study_id>MTI2010-CS02</org_study_id>
    <nct_id>NCT01150526</nct_id>
  </id_info>
  <brief_title>Efficacy of a New Delivery System for Beta-hydroxy-beta-methylbutyrate</brief_title>
  <official_title>Efficacy of a New Delivery System for Beta-hydroxy-beta-methylbutyrate</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Metabolic Technologies Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Iowa State University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Metabolic Technologies Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The proposed study will test efficacy of HMB in free acid gel to decrease muscle damage,
      diminish inflammatory response, and improve muscle strength recovery following an acute
      exercise stress. HMB in a free acid gel or in CaHMB capsule form will be administered as
      either a single dose before a bout of acute exercise or in multiple doses (one before and
      three daily doses for the 4 days following the acute exercise). We hypothesize that HMB in
      free acid gel will result in less muscle damage, diminished inflammatory response, and
      improved muscle strength recovery than either a placebo or CaHMB treatment following a bout
      of acute eccentric exercise. Our endpoints will include measurements of: (1) markers for
      muscle damage (CPK and LDH); (2) indicators of inflammation (CRP, TNF-Î±, IL-6, IL-1ra and
      IL-18); and (3) muscle strength recovery and soreness.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2010</start_date>
  <completion_date type="Actual">July 2012</completion_date>
  <primary_completion_date type="Actual">November 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Decrease in muscle damage and inflammation</measure>
    <time_frame>4 days post eccentric exercise bout</time_frame>
    <description>Serum analysis for markers of muscle damage (CPK) and inflammation (IL-6, IL-18, IL1ra, TNF-a, CRP) will be measured at 24, 48, 72, and 96 h post exercise bout</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Improvement in strength recovery and decrease in soreness</measure>
    <time_frame>4 days post eccentric exercise bout</time_frame>
    <description>Muscle strength recovery and soreness will be measured at 24, 48, 72, and 96 h post exercise bout.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">41</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Oral Placebo capsule and one placebo gel dosage given 30 min prior to the acute exercise session. A placebo capsule and placebo gel dosage are then administered 3 times daily during the remainder of the study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CaHMB Pre</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral CaHMB capsule and one placebo gel dosage given 30 min prior to the acute exercise session. A placebo capsule and placebo gel dosage are then administered 3 times daily during the remainder of the study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CaHMB Pre and Post</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral CaHMB capsule and one placebo gel dosage given 30 min prior to the acute exercise session. A CaHMB capsule and placebo gel dosage are are then administered 3 times daily during the remainder of the study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HMB Free Acid Gel Pre</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral placebo capsule and one HMB free acid gel dosage given 30 min prior to the acute exercise session. A placebo capsule and placebo gel dosage are then administered 3 times daily during the remainder of the study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HMB Free Acid Gel Pre and Post</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral placebo capsule and one HMB free acid gel dosage given 30 min prior to the acute exercise session. A placebo capsule and HMB free acid gel dosage are then administered 3 times daily during the remainder of the study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>CaHMB</intervention_name>
    <description>CaHMB capsules with each capsule containing 0.8 g of HMB</description>
    <arm_group_label>CaHMB Pre</arm_group_label>
    <arm_group_label>CaHMB Pre and Post</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>HMB Free Acid Gel</intervention_name>
    <description>HMB Free acid in a gel form with each dose supplying 0.8 g of HMB free acid</description>
    <arm_group_label>HMB Free Acid Gel Pre</arm_group_label>
    <arm_group_label>HMB Free Acid Gel Pre and Post</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo capsules similar in size and color to the CaHMB capsules used in the study</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>CaHMB Pre</arm_group_label>
    <arm_group_label>HMB Free Acid Gel Pre</arm_group_label>
    <arm_group_label>HMB Free Acid Gel Pre and Post</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo Gel Dosage</intervention_name>
    <description>A corn syrup based placebo with flavoring and taste similar to the HMB Free Acid Gel</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>CaHMB Pre</arm_group_label>
    <arm_group_label>CaHMB Pre and Post</arm_group_label>
    <arm_group_label>HMB Free Acid Gel Pre</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Must live within 50 miles of Ames, Iowa

          -  Free of cardiac, liver, pulmonary, and kidney disease

          -  Free of chronic inflammatory disease including rheumatoid arthritis, osteoarthritis,
             inflammatory bowel disease, and psoriasis

          -  Free diabetes mellitus

          -  Not classified as morbidly obese (BMI must be less than 40)

          -  Free of cardiac, liver, pulmonary, and kidney disease

          -  No other serious medical illness

          -  Normal menstrual cycle and not pregnant or lactating

          -  Able to consume supplements and perform required exercise testing

        Exclusion Criteria:

          -  Live more than 50 miles from Ames, Iowa

          -  Presence of cardiac, liver, pulmonary, and kidney disease

          -  Presence of chronic inflammatory disease including rheumatoid arthritis,
             osteoarthritis, inflammatory bowel disease, and psoriasis

          -  Diabetes mellitus

          -  Classified as morbidly obese (BMI is greater than 40)

          -  No other serious medical illness

          -  Abnormal menstrual cycle, pregnant or lactating

          -  Not able to consume supplements and perform required exercise testing
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John A Rathmacher, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Metabolic Technologies Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Iowa State University</name>
      <address>
        <city>Ames</city>
        <state>Iowa</state>
        <zip>50010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 23, 2010</study_first_submitted>
  <study_first_submitted_qc>June 24, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 25, 2010</study_first_posted>
  <last_update_submitted>July 16, 2012</last_update_submitted>
  <last_update_submitted_qc>July 16, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 18, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acute Exercise</keyword>
  <keyword>Muscle Inflammation</keyword>
  <keyword>CaHMB</keyword>
  <keyword>HMB Free Acid Gel</keyword>
  <keyword>Healthy Subjects</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

